|
Congressional:
House Advances Budget Resolution, Faces Challenges on Medicaid Savings
On Thursday, the House advanced the budget resolution passed by the Senate a few days prior, a key step necessary for passing filibuster-proof legislation on President Trump’s priorities. The final vote was 216-214, with Representatives Victoria Spartz (R-IN) and Thomas Massie (R-KY) joining all House Democrats in opposing the measure. The resolution instructs the House Energy and Commerce Committee to find $880 billion in savings—a target many believe cannot be reached without reductions to federal support for the Medicaid program.
House leadership and President Trump have pledged not to cut Medicaid benefits, and some Republicans have stated publicly that they will not support legislation that reduces coverage for vulnerable populations. House health care leaders met Thursday to discuss alternatives, with work requirements emerging as one potential consensus proposal. Speaker Mike Johnson has proposed eliminating fraud, waste, and abuse and blocking undocumented individuals from accessing Medicaid as potential paths to savings, though critics argue these measures are unlikely to meet the full target.
In response to the budget resolution that Democrats say could fast-track deep Medicaid cuts and roll back Affordable Care Act subsidies, Senate Democrats released an open letter on Thursday, warning that Republican-led tax legislation would disproportionately benefit high-income individuals and corporations while reducing health care access for millions of Americans.
Congressional Republicans plan to continue negotiations over the details of budget reconciliation legislation when they return April 28 from the two-week Easter-Passover recess.
House Ways and Means Health Subcommittee Holds Hearing on The Biosimilar Market
On Tuesday, the House Ways and Means Subcommittee on Health held a hearing on the health of the biosimilar market. During the hearing, Republicans expressed criticism of patent abuses, the Inflation Reduction Act (IRA), and pharmacy benefit managers (PBMs), for distorting incentives and creating regulatory and financial barriers that discourage biosimilar development, investment, and adoption. Democrats widely supported the IRA’s cost-saving measures while warning that mass firings and funding cuts under the Trump-Vance administration threaten biosimilar innovation, patient access, and public health infrastructure. The witnesses emphasized that biosimilar adoption and innovation depend on a predictable regulatory environment, adequate reimbursement structures, and continued public investment in early-stage research. Read Mehlman’s hearing summary here.
House Appropriations Committee Examines the Future of PEPFAR
On Tuesday, the House Committee on Appropriations Subcommittee on National Security, Department of State, and Related Programs held a hearing to assess the President’s Emergency Plan for AIDS Relief (PEPFAR) following the expiration of key authorizations and recent disruptions to foreign aid. During the hearing, Subcommittee Chair Mario Diaz-Balart (R-FL) voiced strong support for PEPFAR’s global impact but called for a review to improve accountability and sustainability, citing concerns over a Mozambique incident that violated the Helms Amendment. Democrats, including Ranking Member Lois Frankel (D-FL), emphasized the Trump-era funding freezes and administrative confusion that caused interruptions in care. Witnesses highlighted PEPFAR’s success in saving lives, supporting U.S. national security, and the risks of disengagement. Both parties stressed the need for bipartisan cooperation to ensure the program’s future stability and effectiveness. Read Chair Diaz-Balart's opening statement here, Ranking Member Frankel’s opening statement here, and witness testimonies here.
US Trade Representative Greer Advocates for Reshoring Pharmaceutical Production
On Wednesday, United States Trade Representative Jamieson Greer appeared before the House Ways and Means Committee to provide an update on the Trump administration’s 2025 trade policy agenda. During the hearing, Greer emphasized the importance of reshoring American pharmaceutical production. He also stated that pharmaceuticals were exempt from President Trump’s reciprocal tariffs in order to give the Commerce Department time to review onshoring capabilities. Read Mehlman’s hearing summary here.
Senate Appropriations Committee to Hold Hearing Series on Biomedical Research
On Monday, Senators Susan Collins (R-ME), chair of the Senate Appropriations Committee, and Patty Murray (D-WA), vice chair of the committee, announced that the Senate Appropriations Committee is kicking off a series of hearings focused on biomedical innovation in the United States. The hearing series, titled "Biomedical Research: Keeping America's Edge in Innovation," is part of an effort to focus on biomedical innovation domestically. The first hearing will take place on Wednesday, April 30, where the panel will hear from researchers and stakeholder groups about the state of biomedical innovation in the United States. The second portion of the series will consist of administration officials testifying on the government's role in "investing in and fostering biomedical innovation."
Notable Bills Introduced:
Senators Hassan, Paul, Hickenlooper, Lee Reintroduce Bill to Lower Prescription Drug Prices by Streamlining Generic Drug Approval Process
On Thursday, Senators Maggie Hassan (D-NH), Rand Paul (R-KY), John Hickenlooper (D-CO), and Mike Lee (R-UT) reintroduced bipartisan legislation to streamline the approval process for generic drugs. This legislation aims to help generics enter the market more quickly and lower prescription drug prices for patients by requiring the Food and Drug Administration (FDA) to more clearly identify the specific differences between generic and brand name drugs, thereby streamlining the approval process and lowering prices. Read the press release here and the bill here.
Representatives Boyle, Pallone, Craig, Casar, Schneider, Correa Introduce Bill to Address Cuts to Medicaid and Food Assistance
On Wednesday, Representatives Brendan F. Boyle (D-PA), Ranking Member of the House Budget Committee; Frank Pallone, Jr. (D-NJ), Ranking Member of the Energy and Commerce Committee; Angie Craig (D-MN), Ranking Member of the Agriculture Committee; Greg Casar (D-TX), Chair of the Congressional Progressive Caucus; Brad Schneider (D-IL), Chair of the New Democrat Coalition; and Lou Correa (D-CA), Blue Dog Coalition Co-Chair for Policy and Legislative Strategy introduced the Hands Off Medicaid and SNAP Act. This legislation would ensure access to Medicaid and food assistance through SNAP amidst proposed budget cuts. Read the press release here and the bill here.
Kaine & Banks Introduce Bipartisan Bill to Support Mental Health Care and Substance Use Disorder Recovery
On Tuesday, Senators Tim Kaine (D-VA) and Jim Banks (R-IN), members of the Senate Health, Education, Labor and Pensions (HELP) Committee, introduced the Providing Empathetic and Effective Recovery (PEER) Support Act. This bipartisan legislation aims to strengthen the role of peer support specialists—trained individuals with personal experience in mental health or substance use disorder who support others in recovery through advocacy, mentorship, community connection, goal setting, and sharing resources. Representatives Andrea Salinas (D-OR) and Tracey Mann (R-KS) are leading a companion bill in the House. Read the press release here and the bill here.
Barrasso, Whitehouse Introduce Legislation to Ensure High-Quality Care for America’s Seniors
On Thursday, Senators John Barrasso (R-WY) and Sheldon Whitehouse (D-RI) introduced the Preserving Patient Access to Accountable Care Act. This bipartisan legislation seeks to ensure that seniors receive high-quality health care by renewing incentive-based funding models for Medicare providers. The bill promotes value-based care through Alternative Payment Models (APMs), which reward providers based on the quality rather than the quantity of services delivered. The legislation extends incentive payments for qualifying participants in advanced APMs through payment year 2027 and maintains eligibility thresholds from performance year 2023. Read the press release here and the bill here.
Bilirakis, Moran, and Mullin Sponsor Bipartisan Legislation to Improve Seniors' Access to Hearing Services
On Thursday, Representatives Gus Bilirakis (R-FL), Kevin Mullin (D-CA), and Nathaniel Moran (R-TX) reintroduced the bipartisan Medicare Audiology Access Improvement Act to expand access to hearing and audiology services for seniors. The legislation addresses a barrier that limits Medicare patients’ ability to fully utilize audiology services provided by independent audiologists, despite those services already being covered under existing law. Under current Medicare rules, seniors are restricted from accessing the full range of care that audiologists are trained and licensed to provide. The bill would allow independent audiologists to directly bill Medicare for covered services within their scope of practice, remove the outdated pre-treatment order requirement, and clarify that audiologists can deliver these services at Rural Health Centers and Federally Qualified Health Centers. Read the press release here and the bill here.
Executive Branch:
President Trump Announces Pharmaceutical Tariffs are Coming
On Tuesday, President Donald Trump stated that he plans to impose “major” tariffs on pharmaceutical imports, escalating his push to return drug manufacturing to U.S. soil. “We’re going to be announcing very shortly a major tariff on pharmaceuticals,” he said at a dinner of the National Republican Congressional Committee. “And when they hear that, they will leave China. They will leave other places because they have to sell — most of their product is sold here, and they’re going to be opening up their plants all over the place.” President Trump placed a 90-day pause on reciprocal tariffs that were announced on April 2, but tariffs on Chinese imports remain in place and were raised to 145 percent. It is unclear how the pause may affect the planned pharmaceutical tariffs.
CMS Finalizes 2026 Payment Policy Updates for Medicare Advantage and Part D Programs
On Monday, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2026 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs that finalizes the payment policies for these programs. Payments from the government to MA plans are expected to increase on average by 5.06% from 2025 to 2026, or over $25 billion in MA payments to plans. This is an increase of 2.83 percentage points since the CY 2026 Advance Notice, which is largely attributable to an increase in the effective growth rate.
The Medicare Part D benefit CY 2026 annual out-of-pocket (OOP) threshold is $2,100, which is the original 2025 out-of-pocket cap of $2,000, adjusted based on the annual percentage increase in average expenditures for covered Part D drugs in the U.S. for Part D eligible individuals in the previous year (API). Read the press release here, the MA fact sheet here, and the Part D fact sheet here.
Late last week, on Friday, the Centers for Medicare & Medicaid Services (CMS) issued a final rule for the Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) programs. The Contract Year (CY) 2026 MA and Part D final rule implements changes related to prescription drug coverage, the Medicare Prescription Payment Plan, dual eligible special needs plans (D-SNPs), Star Ratings, and other programmatic areas, including the Medicare Drug Price Negotiation Program. This final rule also codifies existing sub-regulatory guidance in the MA and Part D programs.
The rule also opted not to adopt a Biden administration proposal to allow Medicare to pay for obesity drugs, stating that it was “not appropriate at this time.” A spokesperson for CMS said the agency might consider anti-obesity medications in the future after further reviewing the drugs' costs and benefits. According to Biden administration estimates, the rule would have given an estimated 3.4 million Americans on Medicare and 4 million more adults in Medicaid programs access to the drug. CMS estimated the policy change would cost Medicare $25 billion and Medicaid $15 billion over 10 years. Medicare already covers the drugs to treat diabetes and heart disease. Read the fact sheet here and the final rule here.
CMS Refocuses Medicaid Spending, Ends Funding for Non-Healthcare State Program
On Thursday, the Centers for Medicare & Medicaid Services (CMS) announced it will stop approving federal matching funds for certain state-run programs that are not directly tied to healthcare services. In a letter to the states, CMS said it will no longer support Designated State Health Programs (DSHPs) and Designated State Investment Programs (DSIPs), citing concerns that these expenditures stretch Medicaid’s mission and drain federal resources. CMS said the move is intended to preserve the financial health of the Medicaid program and refocus its core goal: improving health outcomes for vulnerable Americans. Read the press release here and the letter here.
HHS to Restore Public Health Funds to States to Comply with Order
On Monday, the Department of Health and Human Services filed a notice of compliance with a federal judge’s order blocking plans to end over $11 billion in public health care grants to 23 states and Washington, D.C. The agency, however, also filed an emergency motion for reconsideration the same day.
Legal & Other:
Federal Judge Strikes Down Biden Nursing Home Staffing Mandate
On Monday, Judge Matthew J. Kacsmaryk of the U.S. District Court for the Northern District of Texas, vacated a Biden administration rule that set various nursing home staffing requirements for nursing aides, licensed practical nurses, and registered nurses. Kacsmaryk wrote that the requirement that nursing homes have nurses on staff 24 hours a day, seven days a week, exceeds the authority of the Centers for Medicare and Medicaid Services (CMS). He stated that Congress has previously only required nurse staffing for at least eight consecutive hours a day, seven days a week and "CMS lacks authority to issue a regulation that replaces Congress's preferred minimum hours with its own." Kacsmaryk also struck down another provision in the rule requiring residents to receive a certain number of hours of care per day, determined by how many residents a facility has. Currently, the law only states that facilities must provide enough staffing "sufficient to meet the nursing needs" of residents. The American Health Care Association filed the lawsuit in May 2024, claiming the rule exceeded the agencies’ statuary authority, violated federal law, and was arbitrary and capricious. The ruling comes less than a week after the Trump administration’s Justice Department provided a strong defense in a separate lawsuit of the staffing rule in a brief filed with the US Court of Appeals for the Eighth Circuit. The case is Am. Health Care Ass’n v. Becerra. Read the ruling here.
|